Lancet neurology
The most recent articles from:
Lancet Neurol
-
Editorial Comment
Palliative and end-of-life care should not be last or least.
-
Randomized Controlled Trial Multicenter Study
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
-
Randomized Controlled Trial Multicenter Study
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
In the SELECT trial, disease activity was reduced in patients with multiple sclerosis who received daclizumab high-yield process (HYP) for 52 weeks. The primary aim of the SELECTION extension study was to assess the safety and immunogenicity of extended treatment with daclizumab HYP. ⋯ Biogen Idec and AbbVie Biotherapeutics.